2.10
Inovio Pharmaceuticals Inc stock is traded at $2.10, with a volume of 693.60K.
It is up +5.00% in the last 24 hours and up +9.38% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$2.00
Open:
$2.03
24h Volume:
693.60K
Relative Volume:
1.13
Market Cap:
$77.01M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3448
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
+6.60%
1M Performance:
+9.38%
6M Performance:
-51.72%
1Y Performance:
-79.27%
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INO
Inovio Pharmaceuticals Inc
|
2.10 | 73.35M | 832.00K | -135.12M | -124.69M | -6.09 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-14-24 | Initiated | Stephens | Overweight |
Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
Dec-29-21 | Resumed | Jefferies | Hold |
Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
Jun-24-21 | Initiated | Jefferies | Hold |
Mar-23-21 | Initiated | BofA Securities | Neutral |
Feb-12-21 | Initiated | Oppenheimer | Outperform |
Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jun-26-20 | Downgrade | Stifel | Buy → Hold |
May-21-20 | Initiated | The Benchmark Company | Buy |
Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-19-19 | Initiated | ROTH Capital | Buy |
Feb-15-18 | Reiterated | Maxim Group | Buy |
Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
Sep-06-17 | Initiated | Citigroup | Buy |
Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
May-24-17 | Reiterated | Maxim Group | Buy |
Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio shareholders approve board nominees and proposals - Investing.com Australia
Inovio Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines - MyChesCo
Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst - Defense World
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Inovio Pharmaceuticals (INO) Sees Price Target Adjustment by Opp - GuruFocus
Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN
Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus
Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - Insider Monkey
Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus
Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks
Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada
Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... - Yahoo Finance
Inovio Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Advances BLA Submission for INO-310 - GuruFocus
INOVIO Reports First Quarter 2025 Financial Results and Recent B - GuruFocus
Earnings call transcript: Inovio’s Q1 2025 sees narrowed losses, stock rises - Investing.com India
Inovio: Q1 Earnings Snapshot - San Francisco Chronicle
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings: EPS of -$0.51 - GuruFocus
Inovio Pharmaceuticals Q1 Operating Expenses USD 25.1 Million - marketscreener.com
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Inovio Pharmaceuticals Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Options Volatility and Implied Earnings Moves Today, May 13, 2025 - The Globe and Mail
Inovio Pharmaceuticals (NASDAQ:INO) Lowered to “Sell” Rating by StockNews.com - Defense World
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus
Inovio Pharmaceuticals (INO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Inovio at The Citizens JMP Life Sciences Conference: DNA Platform Progress - Investing.com Australia
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Sold by Renaissance Technologies LLC - Defense World
Inovio Pharmaceuticals (NASDAQ:INO) Cut to Sell at StockNews.com - Defense World
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 - Kilgore News Herald
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Announce Q1 2025 Results and Host Live Webcast on May 13 - MyChesCo
Geode Capital Management LLC Boosts Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO to Present at Upcoming Scientific and Investor Conferences - The Bradford Era
INOVIO to Present at Upcoming Scientific and Investor Conferences | INO Stock News - GuruFocus
XTX Topco Ltd Acquires New Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):